Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03671889 · ClinicalTrials.gov registry record · NA
ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease
A NA study of Alzheimer Disease, sponsored by InSightec.
- Recruiting
- Registry status
- NA
- Development phase
- 50
- Enrollment target
- 10
- Study locations
NCT03671889: Recruiting NA study of Alzheimer Disease, sponsored by InSightec.
NCT03671889 is a NA study of Alzheimer Disease that is actively recruiting participants, run by InSightec. The registered enrollment target is 50 participants, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower). The trial reports 10 study locations across 5 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03671889, a NA study of Alzheimer Disease, is actively recruiting participants, sponsored by InSightec.
- RECRUITING
- Registry status
- NA
- Development phase
- 50 participants
- Enrollment target
- 10
- Study locations
Study Summary
The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
Primary Outcome
Rate of adverse events following each treatment through end of study
Conditions Studied
Interventions
- DEVICE Blood Brain Barrier (BBB) Disruption
Study Locations (10)
Florida
- Delray Medical Center & Florida Atlantic University - Delray Beach
- Broward Health Medical Center & The University of Florida - Fort Lauderdale
- University of Florida Health Shands - Gainesville
- Baptist Health South Florida & Florida International University - Miami
- Advent Health - Orlando
- Tampa General Hospital - Tampa
New York
- Weill Cornell Medicine - New York
Ohio
- The Ohio State University -Wexner Medical Center - Columbus
Texas
- University of Texas Southwestern Medical Center - Dallas
West Virginia
- West Virginia University Rockefeller Neuroscience Center - Morgantown
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 50 participants |
| Start Date | 2018-09-28 |
| Est. Completion | 2030-01 |
| Phase | NA |
What NCT03671889 shows while recruiting
NCT03671889 is an interventional study that assigns participants to a tested intervention. The registry caps enrollment at 50 participants, a relatively small participant target, below the 2,751-participant average among 306 other Alzheimer Disease trials with a reported enrollment target (98% lower).
The record links to 1 condition, with Alzheimer Disease appearing as the primary indexed condition, and to 1 intervention - of which Blood Brain Barrier (BBB) Disruption is the first listed.
NCT03671889 lists 10 locations in 5 states (Florida, New York, Ohio).
Frequently Asked Questions
What is clinical trial NCT03671889 about?
NCT03671889 is a clinical study titled "ExAblate Blood-Brain Barrier (BBB) Disruption for the Treatment of Alzheimer's Disease". The purpose of this study is to evaluate the safety and efficacy of the ExAblate Model 4000 Type 2.0 System as a tool to disrupt the blood-brain barrier (BBB) in patients with probable Alzheimer's Disease (AD).
What is the current status of trial NCT03671889?
This trial is currently recruiting. It is a NA study. The enrollment target is 50 participants. The study started on 2018-09-28. Estimated completion is 2030-01.
What conditions does trial NCT03671889 study?
This clinical trial studies the following conditions: Alzheimer Disease.
What interventions are being tested in trial NCT03671889?
The interventions under investigation include: Blood Brain Barrier (BBB) Disruption (DEVICE).
Who is sponsoring clinical trial NCT03671889?
This trial is sponsored by InSightec, which has 38 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03671889 being conducted?
This trial has 10 study locations across Florida, New York, Ohio, Texas, West Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Alzheimer Disease
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Where NCT03671889's enrollment target sits among peer trials
50 210th of 306 higher than 93 of 306 other Alzheimer Disease trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Alzheimer Disease trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
-
I-CARE 2: Mobile Telehealth to Reduce Alzheimer'S-related Symptoms
RECRUITING · NA
-
Brain Outcomes With Lifestyle Change in Down Syndrome
RECRUITING · NA
-
Pulsed Electromagnetic Field Treatment In Patients With Alzheimer's Disease
RECRUITING · NA
-
A Feasiblity Study of Green Activity Program for People Living With Memory Challenges
RECRUITING · NA
-
Connect-Home: Alzheimer's Disease and Related Dementias
RECRUITING · NA
-
Cognitive Vulnerability to Stress in Individuals at Risk for Alzheimer's Disease
RECRUITING · NA
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00200889 · 50 participants · Early Phase 1
Mapping Auricular Vagus Nerve Circuitry
- NCT00409435 · 50 participants · Phase 2
A Study of Pyridostigmine in Postural Tachycardia Syndrome
- NCT01202305 · 50 participants
The Use of Lymph Node Biopsies to Support HIV Pathogenesis Studies
- NCT01225913 · 50 participants · Phase 4
Mechanism(s) of Airflow Limitation During Exacerbation of Asthma
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI